Presently, the core of DN treatment depends on optimal control of the renin-angiotensin-aldosterone (RAAS) system using angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), or aldosterone blockers (spironolactone or finerenone) [12]. This evidence concerns the gene ACE and liver dysplastic nodule.